Skip to content

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03448380
Enrollment
935
Registered
2018-02-28
Start date
2018-02-27
Completion date
2021-03-30
Last updated
2021-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Glucose Monitoring System when used in people with diabetes.

Detailed description

Up to 920 adult subjects, aged 18 years and older with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes, will be enrolled to obtain at least 736 subjects who complete the final visit. Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase). Subjects will maintain a diary/log book of Adverse Events during each phase. Assessment of Adverse Events will occur via self reporting at each monthly visit and/or phone call.

Interventions

Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).

Sponsors

Abbott Diabetes Care
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject must be at least 18 years of age. * Subject must have a diagnosis of type 1 or type 2 diabetes mellitus. * Subject is currently using SMBG for managing their diabetes. * Subject must be able to read and understand English * In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. * Subject must have access to an internet connected computer for uploading data from the blood glucose meter and FreeStyle Libre system. * Subject must be willing and able to provide written signed and dated informed consent.

Exclusion criteria

* Subject is a member of the Site Staff. * Subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes * Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin. * Subject is pregnant or is attempting to become pregnant at the time of enrollment. * Subject is on dialysis at the time of enrollment. * Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. * Subject currently is participating in another clinical trial. * Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Design outcomes

Primary

MeasureTime frameDescription
Safety of the FreeStyle Libre Flash Glucose Monitoring SystemApproximately one year per subject.The study is designed to characterize the safety of the FreeStyle Libre Flash Glucose Monitoring System when used in the intended study population.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026